Literature DB >> 21546626

Activity of fusidic acid against extracellular and intracellular Staphylococcus aureus: influence of pH and comparison with linezolid and clindamycin.

Sandrine Lemaire1, Francoise Van Bambeke, Denis Pierard, Peter C Appelbaum, Paul M Tulkens.   

Abstract

BACKGROUND: Emergence of multidrug-resistant Staphylococcus aureus has triggered a reassessment of fusidic acid (CEM-102, sodium fusidate).
METHODS: Fusidic acid was examined for (1) activity against recent methicillin-resistant S. aureus (MRSA) isolates; (2) modulation of activity by acidic pH; and (3) accumulation by phagocytic cells and intracellular activity against methicillin-susceptible S. aureus (MSSA) and MRSA.
RESULTS: About 96% of strains (N = 94) were susceptible (European Committee on Antimicrobial Susceptibility Testing breakpoint [≤ 1 mg/L]). Activity was enhanced at pH 5.5 (6 dilutions decrease for minimum inhibitory concentration) in parallel with an increase of drug bacterial accumulation (opposite effects for clindamycin; linezolid remained unaffected). Fusidic acid accumulated in THP-1 cells (about 5.5 fold), with further accumulation at pH 5.5 vs pH 7.4. The intracellular activity of Fusidic acid was similar to that of clindamycin and linezolid (maximal relative activity, 0.4-0.6 log(10) colony-forming unit decrease). No cross-resistance to vancomycin or daptomycin was observed.
CONCLUSIONS: Fusidic acid is active against S. aureus in broth as well as intracellularly, with no cross-resistance to other antibiotics.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21546626     DOI: 10.1093/cid/cir165

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  14 in total

Review 1.  Nanostructured platforms for the sustained and local delivery of antibiotics in the treatment of osteomyelitis.

Authors:  Vuk Uskokovic
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2015       Impact factor: 4.889

2.  Calcium phosphate nanoparticles as intrinsic inorganic antimicrobials: In search of the key particle property.

Authors:  Vuk Uskoković; Sean Tang; Marko G Nikolić; Smilja Marković; Victoria M Wu
Journal:  Biointerphases       Date:  2019-05-20       Impact factor: 2.456

Review 3.  Fusidic Acid: A Bacterial Elongation Factor Inhibitor for the Oral Treatment of Acute and Chronic Staphylococcal Infections.

Authors:  Prabhavathi Fernandes
Journal:  Cold Spring Harb Perspect Med       Date:  2016-01-04       Impact factor: 6.915

4.  Inoculum effects of ceftobiprole, daptomycin, linezolid, and vancomycin with Staphylococcus aureus and Streptococcus pneumoniae at inocula of 10(5) and 10(7) CFU injected into opposite thighs of neutropenic mice.

Authors:  Dong-Gun Lee; Yoichi Murakami; David R Andes; William A Craig
Journal:  Antimicrob Agents Chemother       Date:  2013-01-07       Impact factor: 5.191

5.  Cellular pharmacokinetics and intracellular activity of the novel peptide deformylase inhibitor GSK1322322 against Staphylococcus aureus laboratory and clinical strains with various resistance phenotypes: studies with human THP-1 monocytes and J774 murine macrophages.

Authors:  Frédéric Peyrusson; Deborah Butler; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2015-07-13       Impact factor: 5.191

6.  Potent in vitro synergism of fusidic acid (FA) and berberine chloride (BBR) against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA).

Authors:  Rong-mei Liang; Xiao-lan Yong; Yu-qin Duan; Yong-hong Tan; Ping Zeng; Zi-ying Zhou; Yan Jiang; Shi-hua Wang; Yun-ping Jiang; Xiao-chun Huang; Zhao-hui Dong; Ting-ting Hu; Hui-qing Shi; Nan Li
Journal:  World J Microbiol Biotechnol       Date:  2014-08-10       Impact factor: 3.312

Review 7.  Nanoparticulate drug delivery platforms for advancing bone infection therapies.

Authors:  Vuk Uskoković; Tejal A Desai
Journal:  Expert Opin Drug Deliv       Date:  2014-08-11       Impact factor: 6.648

8.  Phase composition control of calcium phosphate nanoparticles for tunable drug delivery kinetics and treatment of osteomyelitis. II. Antibacterial and osteoblastic response.

Authors:  Vuk Uskoković; Tejal A Desai
Journal:  J Biomed Mater Res A       Date:  2012-10-31       Impact factor: 4.396

9.  A new dye uptake assay to test the activity of antibiotics against intracellular Francisella tularensis.

Authors:  Vivien Sutera; Yvan Caspar; Sandrine Boisset; Max Maurin
Journal:  Front Cell Infect Microbiol       Date:  2014-03-18       Impact factor: 5.293

10.  Calcium Phosphate as a Key Material for Socially Responsible Tissue Engineering.

Authors:  Vuk Uskoković; Victoria M Wu
Journal:  Materials (Basel)       Date:  2016-06-01       Impact factor: 3.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.